GIVAUDAN-ROURE WILLING TO DO "LIMITED" PARSOL 1789 SAFETY TRIAL
This article was originally published in The Tan Sheet
Executive Summary
GIVAUDAN-ROURE WILLING TO DO "LIMITED" PARSOL 1789 SAFETY TRIAL in order to obtain monograph status, Givaudan-Roure outside counsel Edward Basile of the Washington, D.C. firm King & Spalding indicated at a May 11 "OTC feedback" meeting with FDA. To address FDA's concerns with the ingredient's safety, Basile said Givaudan- Roure "would develop some limited safety testing in humans" for the LTVA sunscreen.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning